Relapsed Refractory Multiple Myeloma (RRMM) Clinical Trials

7 recruiting

Relapsed Refractory Multiple Myeloma (RRMM) Trials at a Glance

7 actively recruiting trials for relapsed refractory multiple myeloma (rrmm) are listed on ClinicalTrialsFinder across 6 cities in 18 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Seoul, Singapore, and Boston. Lead sponsors running relapsed refractory multiple myeloma (rrmm) studies include Massachusetts General Hospital, Regeneron Pharmaceuticals, and M.D. Anderson Cancer Center.

Browse relapsed refractory multiple myeloma (rrmm) trials by phase

Treatments under study

About Relapsed Refractory Multiple Myeloma (RRMM) Clinical Trials

Looking for clinical trials for Relapsed Refractory Multiple Myeloma (RRMM)? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Relapsed Refractory Multiple Myeloma (RRMM) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Relapsed Refractory Multiple Myeloma (RRMM) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 1Phase 2

A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma

Relapsed Refractory Multiple Myeloma (RRMM)
Regeneron Pharmaceuticals150 enrolled2 locationsNCT07455851
Recruiting
Phase 2

A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"

Relapsed Refractory Multiple Myeloma (RRMM)Extramedullary Disease in Multiple MyelomaPMD+4 more
M.D. Anderson Cancer Center34 enrolled1 locationNCT07382739
Recruiting
Phase 1

Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma

Relapsed Refractory Multiple Myeloma (RRMM)
Massachusetts General Hospital25 enrolled3 locationsNCT07032714
Recruiting
Phase 2

ELISA in Relapsed/Refractory MM

Relapsed Refractory Multiple Myeloma (RRMM)
Massachusetts General Hospital30 enrolled3 locationsNCT06832865
Recruiting
Phase 3

A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

Relapsed Refractory Multiple Myeloma (RRMM)
Regeneron Pharmaceuticals410 enrolled159 locationsNCT05730036
Recruiting
Phase 2

Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy

Relapsed Refractory Multiple Myeloma (RRMM)
Seoul National University Hospital40 enrolled1 locationNCT06920251
Recruiting
Phase 1Phase 2

Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma

Relapsed Refractory Multiple Myeloma (RRMM)
YOUNGIL KOH75 enrolled7 locationsNCT06645678